Vol 71, No 3 (2020)
Clinical vignette
Published online: 2020-03-10
Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer
1
, 1, 1, 1, 1, 1
, 1, 1, 1, 1, 1
Abstract
Not required for Clinical Vignette.
Keywords: empagliflozineuglycaemic diabetic ketoacidosispancreas cancer
References
- U.S. Food and Drug Administration. FDA Adverse Events Reporting System — Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System 2019.
- Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393(10166): 31–39.
- Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes Metab. 2018; 20(1): 25–33.
- Limenta M, Ho CSC, Poh JWW, et al. Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors. Clin Drug Investig. 2019; 39(7): 683–690.
- Markabawi D, Kondapi D, Tambe V, et al. When it is not just DKA; diabetic ketoacidosis as a first presentation of pancreatic adenocarcinoma. Am J Emerg Med. 2018; 36(9): 1720.e1–1720.e2.
